Patrick Fettinger, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 88 Route 37, New Fairfield, CT 06812 Phone: 203-746-9660 Fax: 203-746-4186 |
News Archive
Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.
Every year in the United States, about 800,000 people experience a stroke. Many are left with neurological complications such as paralysis on one side of the body, speech and language problems, vision issues, behavioral changes, and memory loss.
The first antiretroviral treatments appeared in 1996. Since then, new and better drugs have been discovered that have almost turned AIDS into a chronic disease.
American Portwell Technology, Inc., a wholly owned subsidiary of Portwell, Inc., a world-leading innovator in the Industrial PC market and a member of the IntelĀ® IoT Solutions Alliance, has launched a portfolio of medical touch monitors and medical all-in-one touch computers to support efforts in response to the COVID-19 pandemic.
› Verified 4 days ago